3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
64
Terminated
11
Unknown
7
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
5
Hodgkin Disease
5
Leukemia, Biphenotypic, Acute
4
Hematologic Neoplasms
4
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Sarcoma
2
Rhabdomyosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Burkitt Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Interventions
Fulvestrant
60
Capecitabine
47
Trastuzumab
46
Letrozole
45
pembrolizumab
42
Carboplatin
41
Paclitaxel
39
Cyclophosphamide
38
ribociclib
37
abemaciclib
36
pertuzumab
34
Blood Specimen Collection
31
Specimen Handling
28
trastuzumab deruxtecan
27
Surveys and Questionnaires
26
Docetaxel
26
Tamoxifen
25
Anastrozole
25
exemestane
24
palbociclib
21
130-nm albumin-bound paclitaxel
21
Magnetic Resonance Spectroscopy
20
Biopsy
19
sacituzumab govitecan
18
eribulin
18
Radiotherapy
18
Gemcitabine
18
olaparib
17
Injections
17
Epirubicin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Breast Neoplasms
×
Filgrastim
×
Clear all
NCT05753618
2026-02-09
REaCT-OGF
Ottawa Hospital Research Institute
Phase 4
Recruiting
242 enrolled